Protein degradation therapies work by exploiting the ubiquitin-proteasome system, the cell’s built-in recycling network. In this process, enzymes known as E3 ligases attach molecular tags called ubiquitin to selected proteins. Once tagged, the proteins are transported to the proteasome, a cellular structure that breaks them down. Molecular glue degraders do not simply block a protein’s activity. Instead, they bring an E3 ligase into contact with a previously unrelated cellular protein, effectively redirecting the ligase so that the target is marked for destruction.

The concept has already transformed thinking about proteins considered difficult or impossible to inhibit with conventional drugs. In 2014, Benjamin Ebert, MD, PhD, president and CEO of Dana-Farber, helped establish that lenalidomide, a multiple myeloma treatment, works by acting as a molecular glue degrader of a transcription factor. Transcription factors often lack the deep binding pockets required for traditional inhibitors, leading researchers to describe them as “undruggable.” Their destruction through induced protein-protein interactions demonstrated that drug discovery could target the presence of a protein rather than merely interfere with its function.

Despite the promise of the technology, currently developed protein degraders rely on only a small fraction of the approximately 600 E3 ligases encoded by the human genome. Dana-Farber’s new platform is designed to explore this largely untapped biological diversity. The system begins by attaching selected E3 ligases to magnetic beads in laboratory wells. Researchers then expose the immobilized enzymes to cellular lysate, which contains the broad mixture of proteins found inside cells, together with a library of chemical compounds.

A compound is considered a potential hit when it binds to an E3 ligase and increases the ligase’s affinity for another protein in the cellular mixture. This induced proximity can cause the recruited protein to accumulate around the drug-bound ligase, creating the molecular arrangement required for degradation. The researchers used mass spectrometry to identify the proteins associated with each ligase-compound combination. This allowed them to determine which cellular proteins might be recruited and tagged for destruction after the complex was introduced into living cells.

The team tested the discovery system against seven E3 ligases and identified an interaction between the protein DDX18 and DCAF11, an understudied member of the E3 ligase family. By progressively narrowing the chemical library, the researchers traced the activity to a compound known as M12. The result initially appeared to offer a straightforward example of a new molecular glue degrader. However, when the investigators attempted to use M12 in cells to eliminate DDX18, the compound failed to produce the expected degradation.

That unexpected failure led the researchers to examine the molecular complex in greater detail. Using cryo-electron microscopy, co-first author Franziska Wachter, MD, and colleagues determined that M12 had undergone a chemical alteration called glutathionylation. This process involves the attachment of glutathione, a small molecule involved in maintaining cellular redox balance, to another molecule or protein. The modification changed M12 into its active form, explaining why the original compound behaved differently in the test tube and in living cells.

The finding suggests that molecular glues may be regulated by the metabolic state of a cell rather than functioning as permanently active compounds. M12 became effective in cells with elevated levels of metabolites associated with oxidative stress, a condition frequently observed in cancer cells because of their altered metabolism, rapid proliferation and demanding growth environment. In principle, this type of activation could allow future degraders to operate preferentially in diseased cells while remaining less active in normal tissue, although extensive research will be required to determine whether such selectivity can be converted into a safe medicine.

Further experiments showed that activated M12 was not restricted to DDX18. By modifying the proteins recruited to the DCAF11 complex, the researchers were able to direct degradation toward several additional targets, including SMARCA2, WEE1 and CDK7, all of which have important roles in cancer biology. The results represent a proof of principle for a scalable discovery strategy rather than the identification of a finished drug candidate. Nevertheless, the work demonstrates how combining chemical screening, proteomics, structural biology and cell-based testing can reveal unexpected forms of degrader activity. Eric Fischer, PhD, and Ebert said the platform could accelerate the discovery of molecular glues that expand the range of cancer-related proteins accessible to therapeutic degradation.

Subject of Research: Systematic discovery of molecular glue degraders and metabolically activated protein degradation for cancer therapy.

News Publication Date: 6-Aug-2026

Web References: Dana-Farber Cancer Institute: https://www.dana-farber.org/ ; Eric Fischer, PhD: https://www.dana-farber.org/find-a-doctor/eric-fischer ; Benjamin Ebert, MD, PhD: https://www.dana-farber.org/find-a-doctor/benjamin-levine-ebert ; Franziska Wachter, MD: https://www.dana-farber.org/find-a-doctor/franziska-wachter

References: Nature, article publication date 5-Aug-2026.

Keywords: molecular glue degraders, targeted protein degradation, E3 ligases, DCAF11, DDX18, M12, glutathionylation, oxidative stress, cancer drug discovery, cryo-electron microscopy, proteomics, molecular biology

Cisplatin, a cornerstone in the treatment of various malignancies, is effective in cancer eradication but carries a significant burden of reproductive toxicity. Women undergoing cisplatin treatment often report diminished ovarian reserve, disrupted hormone levels, and impaired fertility. This dichotomy forms a pressing need for strategies that can safeguard ovarian function during chemotherapy. In this context, the study by Zhu et al. ventures into the realm of cellular pathways to unravel potential protective mechanisms.

Indole-3-carbinol, known for its role in modulating estrogen metabolism and exhibiting anti-carcinogenic properties, emerges as a promising candidate in this research. The authors examined its effects in an animal model subjected to cisplatin therapy. The results revealed that indole-3-carbinol not only preserved the ovarian architecture but also significantly lowered the incidence of fibrotic changes typically induced by cisplatin treatment. This finding underlines the potential of indole-3-carbinol as an adjunct therapy in mitigating chemotherapy-induced ovarian damage.

The study deeply investigates the relationship between ovarian fibrosis and TGF-β1/Smad signaling pathways. TGF-β1, a pivotal cytokine in fibrogenesis, was found to be upregulated in response to cisplatin treatment. This upregulation correlates with enhanced fibrotic activity, which compromises ovarian function and may lead to long-term reproductive health issues. By administering indole-3-carbinol, researchers noted a marked reduction in TGF-β1 expression, suggesting a direct modulatory effect of this compound on fibrotic mechanisms.

To provide a comprehensive understanding of the study’s findings, the research involved histological evaluations to assess the ovarian tissue’s structural integrity post-treatment. The comparison between treated and control groups illustrated that indole-3-carbinol not only mitigated the degree of fibrosis but also supported the follicular count, a critical parameter for assessing ovarian reserve. These histological insights reinforce the biochemical data that highlighted the protective role of indole-3-carbinol against cisplatin’s detrimental effects.

Moreover, the systemic inflammatory response prompted by chemotherapy often exacerbates tissue injury. The study explored the inflammatory cytokine milieu, documenting a notable decrease in pro-inflammatory markers among indole-3-carbinol treated subjects. This observation suggests that beyond fibrosis, indole-3-carbinol may play an integral role in dampening the inflammatory responses associated with cancer treatment, further protecting the ovarian environment.

The implications of this research extend into the arena of clinical applications, especially for women facing the prospect of chemotherapy. Understanding the therapeutic potential of dietary components like indole-3-carbinol opens new avenues for adjunct therapies that align with conventional cancer treatments. This study thus advocates for a more integrated approach that combines pharmacological and nutritional strategies to enhance women’s reproductive health during cancer therapies.

As cancer survivorship improves due to advancements in treatment modalities, fertility preservation and reproductive health have become paramount concerns. The findings from Zhu et al. address these concerns, shedding light on a possible intervention that is both effective and derived from natural sources. The broader acceptance of such compounds could lead to significant changes in how oncologists approach the management of reproductive side effects in female cancer patients.

Continued research is essential to further elucidate the mechanisms through which indole-3-carbinol conveys its protective effects. Future studies should aim to explore varying dosages, routes of administration, and the impact on human ovarian cells to enhance the translational viability of these findings. In a landscape where fertility preservation is becoming a critical aspect of cancer care, compounds that can provide protective strategies against treatment-induced damage will garner significant interest.

Lastly, this groundbreaking study exemplifies the importance of interdisciplinary research, combining oncology, reproductive health, and nutrition. As science continues to unravel the complexities of cancer treatment and the body’s responses, the integration of these various fields will undoubtedly pave the way for more targeted and effective therapeutic strategies. Such collaboration holds the potential to redefine cancer care and create a landscape where patients can undergo treatment while minimizing long-term reproductive consequences.

In conclusion, the exploration of indole-3-carbinol’s role in ameliorating cisplatin-induced ovarian damage marks a pivotal step forward in the quest for holistic cancer treatment options. By addressing both the oncological and reproductive health aspects, researchers are laying the groundwork for a future where cancer treatments are not just about survival but also about preserving the quality of life post-treatment.

Subject of Research: Indole-3-carbinol in alleviating cisplatin-induced ovarian damage.

Article Title: Indole-3-carbinol alleviates cisplatin-induced ovarian damage by inhibiting ovarian fibrosis through the TGF-β1/Smad pathway.

Article References:

Zhu, F., Li, F., Zhang, R. et al. Indole-3-carbinol alleviates cisplatin-induced ovarian damage by inhibiting ovarian fibrosis through the TGF-β1/Smad pathway.
J Ovarian Res (2026). https://doi.org/10.1186/s13048-026-01994-2

Image Credits: AI Generated

DOI:

Keywords: Indole-3-carbinol, cisplatin, ovarian damage, chemotherapy, TGF-β1/Smad pathway, reproductive toxicity, cancer treatment.

Ovarian cancer remains notoriously insidious, often diagnosed at an advanced stage when treatment options are limited. The survival rates are grim, and the need for innovative strategies to combat this disease is urgent. The findings by Krishna et al. suggest that targeting RLIP could represent a novel therapeutic approach in managing ovarian cancer both in terms of inhibiting tumor growth and curtailing metastasis, which is among the most challenging aspects of cancer treatment.

At the heart of this study is RLIP, a protein involved in various cellular processes, including cell signaling, cytoskeletal organization, and membrane trafficking. Previous research hinted at the possibility that manipulating RLIP levels could influence cancer progression. Therefore, the researchers endeavored to explore how RLIP depletion might modulate ovarian cancer dynamics. The results were promising, indicating that reducing RLIP expression led to noticeable decreases in tumor proliferation.

The experimental design of the study was methodologically robust, employing both in vitro cell culture techniques and in vivo mouse models of ovarian cancer. By utilizing various assays, including proliferation and migration assays, the investigators could ascertain the impact of RLIP depletion accurately. They observed that ovarian cancer cells with depleted RLIP exhibited reduced growth rates and exhibited impaired migratory capabilities, a critical factor in metastasis.

Metastasis remains one of the principal challenges in the treatment of ovarian cancer. Tumor cells can disseminate from the ovaries to other organs within the body, often leading to treatment resistance and relapse. The research team’s findings revealed that RLIP depletion significantly curtailed the metastatic potential of ovarian cancer cells, offering a potential strategy for intercepting the spread of the disease. This aspect of their study provides critical insights that could and should be explored further in clinical contexts.

Moreover, the mechanisms by which RLIP exerted its effects were elucidated in detail through a range of cellular assays. The results suggested that RLIP interacts with several signaling pathways known to be pivotal in cancer biology, thus implying that the ability to manipulate RLIP could offer a two-pronged approach: directly suppressing tumor growth while simultaneously inhibiting metastasis.

The significance of this research extends beyond academic curiosity. It lays the groundwork for future clinical trials aimed at validating RLIP as a potential biomarker for ovarian cancer progression. The notion of using RLIP levels as an indicator of disease state paves the way for personalized medicine approaches, potentially enabling clinicians to tailor therapies based on individual RLIP expressions in patients.

In guiding the discourse on ovarian cancer treatment, this research accentuates the need for deeper exploration into the molecular underpinnings of cancer biology. By forging connections between proteins like RLIP and cancer progression, the scientific community is better positioned to develop innovative therapies that can improve patient outcomes.

Further investigations will undoubtedly focus on identifying RLIP inhibitors that could be synthesized for clinical trials. The possibility of leveraging RLIP depletion as a therapeutic strategy raises important questions about combination therapies that involve targeting multiple pathways or integrating RLIP inhibitors with existing treatments. Collaborations between molecular biologists and clinical oncologists will be crucial in refining these therapeutic approaches.

The journey from bench to bedside may be long, but studies like that of Krishna et al. offer a beacon of hope for patients battling ovarian cancer. These findings resonate with the potential to transform not only the clinical landscape of ovarian cancer but also the broader field of oncological research. As scientists continue to explore the protein’s role, one can only hope that further discoveries will follow in short order.

In conclusion, the depletion of RLIP has emerged as a promising avenue for curbing ovarian cancer growth and metastatic spread, as evidenced by the rigorous research by Krishna and his team. The implications of this study stretch far beyond academic inquiry, promising new horizons in the fight against one of the deadliest forms of cancer. With perseverance and innovation, the scientific community continues to push the boundaries of what is possible in the realm of cancer treatment.

As more data emerges and further studies are undertaken, the anticipation of new therapies that emerge from this and similar research endeavors remains a source of inspiration and hope for countless individuals. The link between RLIP and ovarian cancer is not merely a scientific curiosity; it stands as a testament to the resilience of research and the ever-expanding toolkit available in the battle against cancer.

This pivotal research not only highlights the necessity of identifying and validating new therapeutic targets but also reinforces the power of collaboration and interdisciplinary work in evolving cancer treatment paradigms. With each significant discovery, we inch closer to a holistic understanding of cancer mechanisms, bringing us one step nearer to revolutionizing the management of this challenging disease.

In summary, the exploration of RLIP as a potential therapeutic target is a prime example of how investigative research can lead to real change in clinical practices aimed at improving patient survival and quality of life in the face of cancer.

Subject of Research: RLIP depletion and its effects on ovarian cancer growth and metastasis.

Article Title: RLIP depletion suppresses ovarian cancer growth and metastasis.

Article References:

Krishna, B.M., Garg, P., Horne, D. et al. RLIP depletion suppresses ovarian cancer growth and metastasis.
J Ovarian Res (2026). https://doi.org/10.1186/s13048-026-01985-3

Image Credits: AI Generated

DOI: 10.1186/s13048-026-01985-3

Keywords: RLIP, ovarian cancer, metastasis, therapeutic targets, protein depletion, cancer treatment, clinical implications.

Recent studies have highlighted the need for an in-depth investigation into how FMD influences TAM functionalities. TAMs can either support tumor survival and growth or activate anti-tumor immunity, owing to their plasticity. Understanding the molecular mechanisms behind FMD’s effects on TAMs could open up new avenues for therapeutic interventions. A significant area of interest is the ubiquitin-proteasome system (UPS), known for its role in regulating protein degradation and turnover within cells. Fasting has been shown to activate the UPS, leading to an enhanced ability of cells to manage metabolic stresses.

Intriguingly, the Nuclear Factor Erythroid 2-like 1 (NRF1) has gained attention for its potential to mediate changes in gene expression associated with the proteasome. NRF1 is responsible for the transcription of several genes related to the UPS. Examining how NRF1 function might be altered by diets mimicking fasting could reveal critical insights into its role in TAMs during the immune response to cancer. The hypothesized relationship between FMD, NRF1 activity, and the metabolic fate of TAMs suggests a novel mechanism by which caloric restriction could engage immune cells in a manner that promotes anti-tumor immunity.

This research builds on the foundation laid by previous findings that fasting can enhance the immune surveillance mechanisms against tumors. Not only does fasting alter metabolic pathways, but it also modifies the signaling networks that govern immune cell behavior. The induction of NRF1 by fasting or FMD may serve as a central mechanism through which protein turnover is regulated in TAMs, subsequently influencing their capacity to secrete key cytokines like interferon-beta (IFNβ). IFNβ is known for its role in establishing antiviral responses and modulating immune cell functions, making its secretion an important factor in the context of tumor immunity.

The study proposes that the metabolic reprogramming induced by FMD contributes to an increased secretion of IFNβ from TAMs through NRF1-mediated pathways. This raises essential questions about the interplay between dietary practices and immune regulation in the context of cancer treatment. Does the caloric restriction inherent in FMD truly recast the roles of TAMs from tumor promoters to tumor suppressors? Can nutritional interventions be systematically integrated into oncological care to enhance therapeutic responses?

As researchers embark on this intriguing avenue of study, they employ various experimental techniques to unravel the complexities of how FMD impacts cellular behaviors within the tumor microenvironment. Cellular assays, proteomic analyses, and in vivo models will provide substantial data on the expression patterns of NRF1 and the downstream effects on protein metabolism in TAMs under altered nutritional states. The potential for using FMD as an adjunct therapy opens the door to integrative cancer treatment approaches that prioritize not only the direct targeting of tumors but also the supportive modulation of host immune functions.

Moreover, exploring the connections between dietary habits and cancer biology underscores the profound implications of lifestyle choices on health outcomes. As investigations continue, the hope is that findings will not only define the mechanistic pathways driven by FMD but also address how these mechanisms can be leveraged in clinical settings. By optimizing the timing and composition of dietary interventions, oncologists may be able to synergize the effects of pharmacological treatments with those of nutrition, thus broadening the scope of personalized medicine.

Emerging insights into the relationship between fasting, immune modulation, and tumor behavior mark a promising frontier in cancer research. The intricate link between macronutrient availability, immune dynamics, and tumor microenvironment composition poses new questions about how to effectively harness the body’s own biological systems in the fight against cancer. Identifying the molecular players involved in these processes as defined in the context of FMD is crucial for advancing treatment methodologies.

Furthermore, the potential applicability of FMD in managing therapeutic side effects and improving the quality of life for cancer patients remains a critical consideration. As researchers delve deeper into this promising nexus of nutrition and oncology, the ultimate goal remains: to uncover practical guidelines that could lead to a clearer understanding of how dietary strategies can optimize cancer therapy and promote long-term survival.

In conclusion, the study’s focus on the newly discovered roles of NRF1 in modulating the immune response of TAMs under FMD conditions represents a pivotal step in bridging the gap between nutritional science and clinical oncology. Future studies and clinical trials will need to validate the proposed mechanisms and assess the efficacy of FMD as a viable adjunct to existing cancer therapies, reinforcing the notion that our approach to cancer treatment may benefit from a broader perspective that includes dietary elements as powerful tools for enhancement of host immunity.

Subject of Research: Impact of fasting-mimicking diet on tumor-associated macrophages and their anti-tumor immunity mediated by NRF1.

Article Title: Fasting-mimicking diet induces IFNβ secretion in tumor-associated macrophages via NRF1-mediated ubiquitin-dependent proteolysis of Trex1.

Article References:

Li, J., Jiang, W., Tu, G. et al. Fasting-mimicking diet induces IFNβ secretion in tumor-associated macrophages via NRF1-mediated ubiquitin-dependent proteolysis of Trex1. Br J Cancer (2026). https://doi.org/10.1038/s41416-025-03319-4

Image Credits: AI Generated

DOI: 10.1038/s41416-025-03319-4

Keywords: fasting-mimicking diet, tumor-associated macrophages, NRF1, immune modulation, cancer therapy, ubiquitin-proteasome system, interferon-beta, metabolic reprogramming.

Doxorubicin, a cornerstone of cancer chemotherapy, is known for its efficacy in targeting a wide range of tumors. However, its use is significantly hampered by its hepatotoxicity, which manifests as liver injury, ranging from mild enzyme elevation to severe hepatic damage. This study aims to explore how myricetin could serve as a protective agent, potentially reducing the risk of doxorubicin-induced liver toxicity through the modulation of oxidative stress and inflammatory pathways.

The liver plays a crucial role in drug metabolism and detoxification, rendering it particularly vulnerable to the side effects of chemotherapeutic agents like doxorubicin. The researchers started their investigation by establishing an experimental framework to assess the hepatoprotective properties of myricetin. By treating animal models with doxorubicin and administering myricetin simultaneously, they set the stage for a rigorous evaluation of liver functions and structural integrity following exposure to the chemotherapeutic agent.

Myricetin, a flavonoid commonly found in various fruits, vegetables, and herbs, has garnered attention for its potential health benefits, particularly its antioxidant and anti-inflammatory properties. The researchers hypothesized that these characteristics could mitigate oxidative damage and inflammation triggered by doxorubicin, thereby preserving liver function and architecture. Their results indicated that myricetin administration significantly lowered markers of oxidative stress, suggesting a direct protective role against the cellular damage typically induced by chemotherapy.

Moreover, the study delved into the inflammatory aspect of liver damage, a critical consideration given that inflammation often exacerbates tissue injury. The researchers measured the levels of pro-inflammatory cytokines and other inflammatory markers in the liver tissues of the test subjects. Remarkably, they found that myricetin not only reduced oxidative stress markers but also effectively suppressed the inflammatory response associated with doxorubicin treatment. This dual action underscores myricetin’s potential as a powerful adjunct therapy in chemotherapy protocols.

The mechanisms through which myricetin exerts its protective effects were explored in depth, contributing valuable insights to the understanding of liver pharmacology. The study identified key signaling pathways through which myricetin mediates its antioxidant effects. For instance, the activation of Nrf2, a transcription factor known to regulate the expression of antioxidant proteins, was notably enhanced in the presence of myricetin. This finding illuminates an intriguing avenue for further research, as targeting the Nrf2 pathway may provide a strategic approach to bolster hepatic defense mechanisms against chemotherapeutic agents.

Additionally, the study’s findings prompted further investigations into the possible synergistic effects of myricetin with other chemotherapeutic agents. This line of inquiry holds promise for the development of combination therapies that maximize anti-cancer efficacy while minimizing hepatotoxic risks. As the quest for precision medicine continues, such insights can guide clinicians in tailoring treatment plans that better accommodate individual patient responses and minimize adverse effects.

In evaluating the clinical implications of these findings, it is crucial for oncologists and researchers to consider how myricetin could be integrated into existing treatment paradigms. The potential for myricetin to act as a hepatoprotective agent offers a glimmer of hope for patients facing the deleterious effects of chemotherapy on liver health. As the study suggests, enhancing the liver’s resilience may not only improve the quality of life for patients undergoing cancer treatment but could also potentially increase the maximum tolerable doses of chemotherapeutics, thus enhancing therapeutic outcomes.

Public response to research such as this often hinges on the relatability of the findings to everyday experiences. As awareness grows regarding the side effects of cancer treatments, the desire among patients and healthcare providers for protective measures intensifies. Studies like those by Sabir and Dyary resonate with a broad audience, opening informed discussions about the integration of natural compounds into the realm of modern medicine.

Furthermore, the widespread availability of myricetin-rich foods presents an exciting opportunity for preventive health measures. Educating patients about dietary sources of myricetin—such as berries, nuts, onions, and tea—could foster a proactive approach to liver health during chemotherapy. The convergence of dietary habits and pharmacotherapy could empower patients to take an active role in their treatment journeys, potentially mitigating some adverse effects associated with conventional therapies.

As this research paves the way for future studies, the authors emphasize the need for clinical trials to further explore the efficacy and safety of myricetin in human populations. Confirmation of these benefits in clinical settings will be critical to establish guidelines for its use alongside standard treatments. Such endeavors could lead to significant advancements in the optimization of cancer care, ensuring that patients receive comprehensive support throughout their treatment experiences.

In summary, the study conducted by Sabir and Dyary offers compelling evidence for the potential of myricetin to mitigate liver damage induced by doxorubicin. By elucidating the mechanisms of oxidative stress and inflammation modulation, this research opens new pathways for exploration in both laboratory and clinical settings. The integration of natural agents such as myricetin into cancer treatment regimens could mark a transformative step toward improved patient outcomes, underlining the importance of a multidisciplinary approach in the fight against cancer.

This groundbreaking research not only contributes to the scientific community’s understanding of chemotherapeutic safety but also emphasizes the vital role of nutrition and natural compounds in enhancing health during disease management. As the conversation around personalized medicine continues to evolve, the implications of these findings may eventually extend beyond the laboratory and into the lives of countless individuals navigating the complexities of cancer treatment.

Subject of Research: Doxorubicin-induced liver damage and the protective effects of myricetin.

Article Title: Myricetin protects against doxorubicin-induced liver damage by modulating oxidative and inflammatory pathways.

Article References:

Sabir, L.M., Dyary, H.O. Myricetin protects against doxorubicin-induced liver damage by modulating oxidative and inflammatory pathways. BMC Pharmacol Toxicol (2026). https://doi.org/10.1186/s40360-026-01088-1

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01088-1

Keywords: Myricetin, Doxorubicin, Liver Damage, Oxidative Stress, Inflammation, Hepatoprotective, Cancer Therapy, Chemotherapy.

The alkaloids in question operate through a complex biochemical pathway, specifically modulating the interplay between the p38 and p53 proteins. The p38 protein, part of the mitogen-activated protein kinase (MAPK) family, is known for its role in regulating cellular responses to stress and inflammation. The p53 protein, often dubbed the “guardian of the genome,” safeguards cellular integrity by regulating the cell cycle and promoting apoptosis in response to DNA damage. Both of these proteins are crucial players in cancer biology, and their manipulation presents a novel approach to cancer treatment.

In detail, the study conducted by Gao, B., Sui, X., and Choe, H., alongside their colleagues, meticulously explored how these alkaloids induce apoptosis in ovarian cancer cell lines. Utilizing a series of in vitro experiments, the researchers noticed a pronounced increase in apoptotic markers, indicating that the alkaloids successfully trigger cancer cell death. This finding underscores the potential of natural compounds derived from plants to act as powerful anti-cancer agents.

Moreover, the inhibition of cell migration is a pivotal aspect of cancer treatment, as migration facilitates metastasis, leading to cancer spreading to other body parts. The alkaloids from Scutellaria Barbata showed promising results by significantly reducing the migratory capabilities of the ovarian cancer cells in the studied models. The implications of this are profound, as limiting migration may substantially improve patient prognosis and survival rates.

What sets this study apart is its focus on the p38-p53 signaling pathway, an area that has garnered increasing attention in recent oncology research. By demonstrating that alkaloids can enhance p53 activity through the p38 pathway, the researchers have opened the door for deeper investigations into targeted therapies that leverage this mechanism. The ability to carefully modulate these pathways could lead to the creation of drugs that are both effective and have fewer side effects compared to conventional chemotherapeutic agents.

The exploration of natural compounds like those from Scutellaria Barbata is not merely a curiosity; it represents a vital shift in cancer research. Scientists are increasingly recognizing the therapeutic potential of botanical alkaloids, which have evolved over millennia to possess unique bioactive properties. The study serves as a testament to the possibilities that lie within nature, highlighting the need for continued research in this area.

As the implications of these findings are further analyzed, questions arise about the optimal administration of the alkaloids in clinical settings. Could they be used in conjunction with existing therapies, or might they serve as standalone treatments? The pharmacokinetics and bioavailability of these alkaloids will also be central to future research. Understanding how these compounds are metabolized in the human body will be essential for evaluating their therapeutic effectiveness and safety profiles.

Additionally, the study invites an exploration of how these findings can be translated into clinical practice. The prospect of clinical trials examining the efficacy of alkaloid-based therapies in human subjects could provide invaluable insights into their potential as treatment options for ovarian cancer and other malignancies. Collaboration between researchers, clinicians, and pharmaceutical companies will be paramount in translating laboratory success into real-world therapeutic outcomes.

This research reinforces the notion that innovation in cancer treatment does not solely reside within synthetic compounds. A broader understanding of biological systems and the integration of traditional medicine with modern scientific approaches could pave the way for novel therapies. As we delve deeper into the mechanisms of cancer biology, studies such as this highlight the synergy that can arise from interdisciplinary research.

In summary, the study by Gao and colleagues signifies an exciting advancement in our understanding of ovarian cancer treatment, showcasing the potential of Scutellaria Barbata-derived alkaloids. By triggering apoptosis and restricting cell migration through pivotal signaling pathways, these compounds may offer a beacon of hope for those affected by this formidable disease. The ongoing exploration of these natural products holds promise for innovative therapies that could revolutionize how we approach cancer treatment in the future.

As research progresses, the community remains hopeful that the insights gained from this study can lead to tangible health benefits for patients. The focus now shifts to the next steps in research and clinical application, ensuring that the promise of natural compounds does not remain theoretical but transforms into practical, life-saving interventions. Ongoing studies and trials will be essential in determining how these compounds can be effectively utilized in the fight against ovarian cancer—a fight that continues to challenge researchers and clinicians alike.

In conclusion, the findings from Gao, Sui, Choe, and their team represent a significant leap forward in oncology research. The connection between traditional herbal medicine and modern molecular biology exemplifies the potential for innovation in cancer therapies. As we witness an ongoing evolution in the understanding of cancer mechanisms and treatments, the future looks promising for patients facing ovarian cancer and other related malignancies.

Subject of Research: Alkaloids from Scutellaria Barbata and their effects on ovarian cancer.

Article Title: Alkaloids isolated from Scutellaria Barbata D. Don trigger apoptosis and inhibit migration by modulating the p38-p53 pathway in ovarian cancer.

Article References:
Gao, B., Sui, X., Choe, H. et al. Alkaloids isolated from Scutellaria Barbata D. Don trigger apoptosis and inhibit migration by modulating the p38-p53 pathway in ovarian cancer. J Ovarian Res 18, 301 (2025). https://doi.org/10.1186/s13048-025-01840-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01840-x

Keywords: Alkaloids, Scutellaria Barbata, ovarian cancer, apoptosis, p38, p53, cell migration, natural compounds, oncology, therapeutic strategies.

Cancer stem cells are unique cellular entities that possess the capability to self-renew and differentiate into various cell types, spurring the heterogeneous population of tumor cells. This property makes them central to the development and progression of tumors, as well as to treatment resistance and relapse. The recent findings presented in this study suggest that these CSCs are not merely passengers in tumor development but rather active participants that shape the dynamics of their microenvironment.

A pivotal aspect of this research is the comprehensive genomic profiling of CSCs, which has revealed an array of mutations and epigenetic changes that distinguish them from their differentiated progeny. These alterations contribute significantly to the aggressiveness of tumors and are linked to the CSCs’ ability to evade conventional therapies. Understanding these genomic landscapes is crucial for devising effective treatment strategies that specifically target these resilient cells.

Moreover, the tumor microenvironment plays a significant role in modulating the behavior of CSCs. The study highlights the complex interactions between CSCs and various cell types, including stromal cells, immune cells, and extracellular matrix components. These interactions not only support the survival and proliferation of CSCs but also influence their ability to metastasize to distant sites in the body.

The findings of this study underscore the importance of targeting not just the tumor cells but the entire ecosystem within the tumor microenvironment. This holistic approach may lead to the development of novel therapies that excel beyond traditional methods that often fail due to the adaptive capacity of CSCs. Therapies designed to disrupt the supportive interactions and signals within the tumor microenvironment could prove essential in overcoming therapeutic resistance.

In addition, the study explores various therapeutics that are being investigated for their effectiveness against CSCs, including monoclonal antibodies, small molecule inhibitors, and immunotherapies. By delineating the molecular pathways involved in CSC maintenance and proliferation, this research sets the stage for the identification of biomarkers that could help predict patient responses to these treatments.

An important consideration in developing therapies targeting CSCs is the issue of heterogeneity. Tumors are characterized by a diverse population of cells, and not all CSCs exhibit the same genomic characteristics. This heterogeneity must be factored into therapeutic design to ensure that treatments are effective across varying tumor subtypes. The study suggests that personalized medicine approaches, utilizing detailed genomic and proteomic profiling, may be crucial in tailoring therapies to individual patients.

Furthermore, the research emphasizes the potential of leveraging novel delivery systems that could effectively target CSCs while minimizing off-target effects on normal tissues. Nanoparticles and other advanced drug delivery technologies could be optimized to deliver cytotoxic agents directly to CSCs, enhancing the efficacy and safety of treatment regimens.

Understanding the role of the immune system within the tumor microenvironment is another vital point raised in this research. The immune landscape surrounding tumors can either support CSC survival or trigger their destruction. By deciphering how CSCs interact with immune cells, researchers can explore more effective immunotherapies that enhance the body’s natural defenses against cancer.

The study also highlights the promise of combining therapies that target both CSCs and the tumor microenvironment. Synergistic approaches that utilize conventional chemotherapy alongside agents that specifically eradicate CSCs could offer a dual attack against tumors, potentially reducing the likelihood of relapse and treatment failure. The integration of these strategies may well represent the future of cancer treatment.

This comprehensive investigation into genomic landscapes and therapeutic perspectives of cancer stem cells not only advances our understanding of tumor biology but also opens up exciting avenues for future research. As outlined by the authors, continued exploration into the intersection of genetics, tumor microenvironment interactions, and treatment modalities will be essential to make significant strides in cancer therapy.

As researchers delve deeper into the complexities of cancer stem cells and their environments, the hope is that innovative treatment options will emerge, providing better outcomes for patients battling this formidable disease. The findings of Shrestha et al. herald a new era in the quest for effective cancer therapies that address the challenges posed by the resilient and elusive nature of cancer stem cells.

In summary, this pivotal study is a significant contribution to the cancer research field. It not only reviews existing knowledge of cancer stem cell biology but also emphasizes the critical need for a multifaceted approach to combat cancer effectively. Equipped with these insights, the scientific community is better positioned to develop therapies that truly penetrate the core of cancer’s resilience and offer hope to patients worldwide.

Subject of Research: Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment.

Article Title: Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment.

Article References:
Shrestha, P., Lee, D., Giri, A. et al. Genomic landscapes and therapeutic perspectives of cancer stem cells in the tumor microenvironment. J. Pharm. Investig. (2025). https://doi.org/10.1007/s40005-025-00794-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s40005-025-00794-y

Keywords: cancer stem cells, tumor microenvironment, genomic landscapes, therapeutic perspectives, treatment resistance, personalized medicine, immunotherapy, drug delivery systems.

The role of nuclear export in cellular processes cannot be overstated; it is an essential mechanism that regulates the transportation of proteins and RNA out of the nucleus. This process is vital for various cellular functions, including gene expression and cellular responses to environmental stimuli. Selinexor operates by inhibiting this export, thereby retaining specific proteins in the nucleus that are crucial for regulating cell growth and migration. Such a mechanism offers an exciting avenue for intervention in conditions characterized by uncontrolled cellular proliferation and migration, such as cancer.

In the study by Öztatlıcı et al., male germ cells were subjected to Selinexor treatment, and a series of assays were conducted to determine the compound’s effects on cell viability and migration. The results were compelling. Selinexor not only reduced the proliferation of male germ cells but also significantly impeded their migratory capabilities. This finding has profound implications, particularly in the context of understanding fertility and the influence of pharmacological agents on male reproductive health.

The significance of such research extends beyond mere cellular biology; it encompasses broader implications for health and medicine. By elucidating the mechanisms through which Selinexor exerts its effects, researchers can begin to formulate strategies for addressing a variety of reproductive and oncological conditions. This link between basic science and potential clinical application is a hallmark of progress in biomedical research and can pave the way for novel therapeutic approaches.

As the scientific community delves deeper into the interplay of pharmacology and reproductive health, the insights gained from studies like these could contribute to developing new treatment protocols for male infertility or improve outcomes for patients undergoing cancer therapies that adversely affect germ cell function. The dual role of Selinexor as both an anti-proliferative and anti-migratory agent underscores the potential for repurposing existing drugs to target new diseases.

In an age where precision medicine is becoming increasingly paramount, the specificity of Selinexor presents a compelling case for its use in targeted therapeutic strategies. Researchers are continuously seeking compounds that can effectively target malignant cells while minimizing harm to surrounding healthy tissues. Selinexor’s selective nature offers a promising alternative, and further exploration could yield valuable insights into its full therapeutic potential.

Moreover, the in vitro nature of this study allows for a controlled environment, where variables can be meticulously managed. This aspect of the research is vital as it establishes a foundational understanding that can later be translated into in vivo studies. Future research should aim to investigate the efficacy of Selinexor in animal models, examining how these results may vary in a more complex biological system.

As studies of this nature progress, they contribute to a growing body of literature emphasizing the need for integrative approaches to understanding male reproductive health. The nuances of germ cell biology must be acknowledged as we move forward; factors such as environmental influences, lifestyle choices, and genetic predispositions all play vital roles in shaping male fertility and health.

At the heart of these discussions is the notion that scientific breakthroughs often stem from understanding fundamental biological processes. Selinexor’s ability to modulate these processes invites further scrutiny and experimentation, urging researchers to explore the implications not only for germ cells but also for other cell types that rely on similar mechanisms.

The research community is abuzz with the promise of compounds like Selinexor. As more studies elucidate its mechanisms and therapeutic applications, the anticipation of a new frontier in pharmacological treatment for reproductive health challenges looms on the horizon. Awareness of such innovative research is crucial, as it encourages funding, collaboration, and public interest in the science behind male reproductive health.

In conclusion, the work conducted by Öztatlıcı and peers is a testament to the innovative spirit of contemporary biomedical research. By shedding light on the anti-proliferative and anti-migratory effects of Selinexor on male germ cells, the team has paved the way for further investigations that could eventually lead to groundbreaking therapeutic strategies benefiting countless individuals facing fertility and health challenges. The intersection of science and practical application is a journey, one that we must collectively embrace as we seek solutions to complex health issues.

The future of this research holds immense promise, and the scientific community stands at the precipice of discovery, equipped with the tools required to navigate the complexities of cellular behavior, pharmacology, and human health. Selinexor represents not just a compound but a beacon of hope for advancements in male reproductive health, offering a glimmer of possibility in an often-overlooked field of study.

As researchers continue to pursue the depth of knowledge surrounding Selinexor and other novel agents, we can anticipate a transformation in our understanding of male fertility and reproductive biology. The quest for answers is ceaseless, but with endeavors such as the one by Öztatlıcı and colleagues, it becomes increasingly clear that we are moving closer to discovering solutions that may one day enhance human health and wellbeing.

Subject of Research: Inhibitory effects of Selinexor on male germ cells

Article Title: Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro.

Article References:

Öztatlıcı, M., Zada, P.R., Çolaksel, R.B. et al. Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro. BMC Pharmacol Toxicol 26, 196 (2025). https://doi.org/10.1186/s40360-025-01034-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40360-025-01034-7

Keywords: Selinexor, nuclear export, male germ cells, anti-proliferative, anti-migratory, pharmacology, reproductive health, biomedical research.

Central to the canonical Wnt pathway, TCF/LEF proteins act as the ultimate transcriptional effectors, translating the influx of β-catenin signals into discrete gene expression programs. According to co-author Yusuke Higuchi from the Beckman Research Institute, these proteins do not simply serve as passive endpoints but engage in a highly regulated interplay with diverse co-repressors, chromatin remodelers, and layers of post-translational modifications, a complexity that science is only beginning to decode with precision.

The review underscores an intriguing facet of Wnt transcriptional regulation: the Wnt enhanceosome is pre-assembled in a poised state even before signal activation. This arrangement ensures that upon β-catenin’s translocation into the nucleus, the transcriptional machinery can swiftly respond, enabling rapid gene expression changes pivotal for cellular fate decisions. Such molecular pre-organization challenges previous models that viewed enhanceosome assembly as purely signal-induced.

A significant regulatory axis detailed in the analysis involves the ubiquitin-proteasome system, particularly the clearance of the Groucho/TLE co-repressor through UBR5-mediated ubiquitination. This event is crucial for dislodging repression and allowing β-catenin to interact with TCF/LEF factors effectively. Furthermore, the study highlights the phenomenon of context-dependent switching between TCF isoforms, where alternative splicing modulates transcriptional output to fine-tune cellular responses in diverse tissues and pathological states.

Phosphorylation of TCF/LEF proteins by kinases such as TNIK (TRAF2 and NCK-interacting kinase) and HIPK2 (homeodomain-interacting protein kinase 2) emerges as another vital layer of control, dynamically influencing DNA binding affinity and co-factor interactions. These post-translational modifications offer a mechanistic basis for the adaptability and selectivity of Wnt target gene regulation, underpinning the pathway’s roles in development and disease.

Perhaps most notably, the review documents the translational leap from molecular insights to clinical applications. The TNIK inhibitor INS018_055, a product of cutting-edge artificial intelligence-driven drug discovery, has successfully passed Phase II clinical trials for idiopathic pulmonary fibrosis (IPF). This drug demonstrated a statistically significant attenuation of lung function decline over 52 weeks, marking a pivotal validation of targeting downstream Wnt pathway kinases rather than upstream components, which traditionally carry higher toxicity risks.

This clinical milestone represents the first robust instance where modulation of TCF/LEF regulatory kinases has been shown to safely and effectively recalibrate Wnt signaling in human patients. Higuchi accentuates that this approach may overcome longstanding hurdles in targeting Wnt-driven pathologies by circumventing the toxicity commonly associated with broad Wnt inhibitors that disrupt the pathway at more proximal points.

Despite these advances, the review candidly acknowledges the challenges inherent to directly targeting TCF/LEF proteins themselves. Their intrinsically disordered β-catenin binding domains render conventional small-molecule binding approaches ineffective, prompting exploration into next-generation modalities such as PROTACs (proteolysis targeting chimeras) and AI-designed protein scaffolds capable of precise interaction with these elusive regions.

The authors emphasize that selective modulation of TCF/LEF activities opens a promising therapeutic window for a spectrum of diseases including cancer, fibrosis, and metabolic disorders, potentially offering benefits without the deleterious side effects that have hampered prior Wnt pathway targeting efforts. This nuanced control ensures that Wnt signaling can be fine-tuned rather than globally inhibited, preserving essential physiological functions.

Moreover, the review delves into the structural complexity imparted by alternative splicing of TCF/LEF transcripts. Such splicing generates isoforms with differential domain compositions—altering DNA-binding properties, co-regulator recruitment, and transcriptional potency—thus enabling context-specific transcriptional landscapes that align with cellular identity and environmental cues.

The interplay between TCF/LEF proteins and chromatin remodeling complexes further enriches the regulatory network, influencing Wnt target accessibility and epigenetic states. This dynamic chromatin context orchestrates a multifaceted transcriptional environment wherein signal integration occurs, reinforcing the pathway’s adaptability.

Finally, the researchers speculate on the future perspectives enabled by advances in synthetic biology and computational protein design. These technologies could revolutionize the ability to engineer bespoke modulators of TCF/LEF function with unparalleled specificity, potentially heralding a new era of personalized molecular therapies tailored to the intricate regulation of the canonical Wnt pathway.

In summary, this landmark review not only clarifies the molecular intricacies of TCF/LEF-driven transcriptional control within the canonical Wnt pathway but also propels the field toward innovative therapeutic strategies. Harnessing such detailed mechanistic insights promises to transform treatment paradigms for a range of Wnt-associated diseases, delivering precision interventions that reconcile efficacy with safety.

Subject of Research: Molecular mechanisms of TCF/LEF-mediated transcription in the canonical Wnt signaling pathway.

Article Title: (Not explicitly provided in the content)

News Publication Date: (Not explicitly provided in the content)

Web References: http://dx.doi.org/10.1016/j.cmp.2025.09.004

Image Credits: The authors.

Keywords: Drug discovery, Wnt signaling, TCF/LEF transcription factors, cancer, fibrosis, TNIK inhibitors, idiopathic pulmonary fibrosis, transcriptional regulation, co-repressors, chromatin remodeling, post-translational modifications, alternative splicing.

The significance of studying ENE arises from its potential to reshape treatment paradigms for oral cavity cancers. This retrospective analysis underscores ENE as a harbinger of aggressive disease behavior, marking patients with this feature for enhanced scrutiny and intervention. Previous studies have indicated that the presence of ENE correlates with poor prognostic outcomes, often translating to a higher likelihood of recurrence and decreased overall survival. Thakur et al. provide compelling evidence to support these assertions, reiterating the need for heightened awareness among clinicians regarding ENE’s role in guiding therapeutic decisions.

In their analysis, the authors quantify the prognostic impact of ENE on various patient cohorts, revealing a clear association between ENE and diminished survival rates. By meticulously examining clinical data from a diverse group of patients, the researchers identify how the presence of ENE alters the course of the disease, often requiring a more aggressive treatment approach. This insight is particularly relevant in the context of personalized medicine, where tailoring therapy to the individual characteristics of a tumor is paramount. The authors argue that understanding the nuances of ENE can lead to more effective treatment regimens.

The findings have profound implications for the management of patients with oral cavity cancers. Traditionally, treatment for these cancers has followed a standard protocol primarily based on tumor staging, but this study suggests a shift towards incorporating ENE as a critical variable in treatment planning. For instance, patients exhibiting ENE may benefit from more intensive therapies, such as chemoradiation, as opposed to surgery alone. This could lead to improved outcomes and reduced recurrence rates, effectively altering the trajectory of treatment for those most at risk.

Moreover, the research highlights the necessity for oncology professionals to engage in discussions regarding the significance of ENE during multidisciplinary tumor board meetings. Oncologists, surgeons, and radiologists must collaborate to devise comprehensive treatment strategies that account for ENE’s presence. Integrating ENE into routine clinical assessments can facilitate a more tailored therapeutic approach, ensuring that patients receive care that corresponds with the aggressiveness of their disease.

As the medical community continues to grapple with the complexities of cancer treatment, understanding the biological underpinnings of ENE enhances the broader discourse on tumor behavior and response to therapy. The authors elucidate how ENE may serve as a biological indicator of tumor aggressiveness, suggesting that the underlying mechanisms driving this feature could provide further insights into the disease process. Research aimed at elucidating these mechanisms can reveal potential therapeutic targets, ultimately contributing to the development of novel treatment modalities.

In terms of patient outcomes, the study by Thakur et al. aligns with a growing body of literature advocating for the integration of prognostic factors into clinical practice. Historically, the landscape of cancer treatment has been primarily focused on histological classifications and staging. However, with emerging evidence emphasizing markers like ENE, clinicians are urged to adopt a more holistic approach in evaluating risk and tailoring therapies accordingly. The need for continuous education and training in recognizing the implications of ENE is apparent, as it equips healthcare providers to deliver informed and effective care.

The implications of this research extend beyond immediate clinical applications; they pave the way for future investigations aimed at refining diagnostic and therapeutic frameworks for oral cavity cancers. As healthcare systems worldwide grapple with the complexities of cancer care, the integration of studies such as this one into practice can facilitate the development of evidence-based guidelines that incorporate prognostic markers like ENE. This evolution in cancer management fosters an environment where patient outcomes become significantly improved, driven by a foundation of robust clinical evidence.

In light of the findings, the researchers advocate for the necessity of incorporating ENE into staging systems and clinical guidelines. The incorporation of extensive clinical data enables healthcare professionals to better stratify patient risk and customize treatment approaches based on individual prognostic factors. Emphasizing collaborative efforts among oncologists, radiation therapists, and surgeons will yield a more comprehensive understanding of how best to combat the complexities of oral cavity cancers.

In conclusion, the retrospective analysis conducted by Thakur and colleagues elucidates the critical role of extranodal extension as a prognostic factor in oral cavity cancers. As the medical community seeks to enhance treatment outcomes for patients undergoing therapy, understanding the implications of ENE becomes imperative. This research not only amplifies the importance of ENE in clinical decision-making but also sets the stage for future exploration aimed at establishing more effective management strategies. By emphasizing the prognostic potential of ENE, the authors have created a compelling case for its integration into modern oncological practice, ultimately advancing the field of cancer care.

Moreover, ongoing research should continue to examine the interplay between ENE and treatment outcomes. Investigating the biological mechanisms by which ENE influences tumor behavior could uncover innovative therapeutic targets and pathways. Such insights may yield new strategies that not only improve survival rates for affected individuals but also enrich our understanding of tumor biology, leading to broader applications in oncology.

As we move forward into an era of precision medicine, the study of extralymphatic manifestations such as ENE will undoubtedly play a pivotal role in personalizing cancer treatment. By harnessing the knowledge gleaned from retrospective analyses, forward-thinking oncologists can implement change in clinical practice that stands to greatly benefit patients. The future of oral cavity cancer treatment lies in how well we can leverage findings like those presented by Thakur et al., merging rigorous science with impactful patient care strategies.

Through concerted efforts and continuous research, the complexities of oral cavity cancers can be navigated, fostering hope amidst a challenging landscape. The findings on ENE not only beckon a re-evaluation of treatment methodologies but underscore the dynamic nature of cancer as a disease that requires adaptability, innovation, and a patient-centric approach to care.

As we reflect on the implications of this research, let us remain committed to advancing our understanding of oral cavity cancers and their management. Collaborating across disciplines, sharing insights, and embracing novel findings will be essential as we redefine the standards of care, paving the way for a brighter future in oncology.

Subject of Research: Prognostic impact of extranodal extension in oral cavity cancers

Article Title: Prognostic impact of extranodal extension in oral cavity cancers: a retrospective analysis and implications for treatment intensification

Article References:

Thakur, P., I, V., Dwivedi, A. et al. Prognostic impact of extranodal extension in oral cavity cancers: a retrospective analysis and implications for treatment intensification.
J Cancer Res Clin Oncol 151, 314 (2025). https://doi.org/10.1007/s00432-025-06337-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06337-0

Keywords: Extranodal extension, oral cavity cancers, prognostic factors, treatment intensification, personalized medicine, cancer prognosis.